Compare HUDI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUDI | CMMB |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.4M |
| IPO Year | 2019 | 2023 |
| Metric | HUDI | CMMB |
|---|---|---|
| Price | $0.42 | $1.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 322.5K | 102.3K |
| Earning Date | 06-29-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $27.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.01 |
| 52 Week High | $1.67 | $3.44 |
| Indicator | HUDI | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 15.42 | 24.22 |
| Support Level | N/A | N/A |
| Resistance Level | $0.84 | $1.89 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 20.01 | 5.36 |
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.